What Is Fulphila?

Pegfilgrastim, which is also known by the brand name, Neulasta, is a hematopoietic agent that is used to treat neutropenia. Neulasta was the first medication produced based on the active element pegfilgrastim. Pegfilgrastim is not a hazardous drug, nor is it a form of chemotherapy.

Based on Neulasta, several different biosimilars have been produced, one of which is called Fulphila. Fulphila is similar to Neulasta in its mechanism of action, administration route, strength, and dosage.

Cơ chế hoạt động

Pegfilgrastim is a blood cell colony-stimulating agent (CSA) and has been used successfully by cancer patients to stimulate the growth of white blood cells, more specifically neutrophils. It does this by stimulating the production of neutrophils directly from the bone marrow.

Precautions

Unless approved by your physician, pegfilgrastim is generally not recommended for:

• Patients who have an allergy to human granulocyte colony-stimulating factors (CFS) such as filgrastim or pegfilgrastim products. The needle cap on the prefilled syringe contains natural rubber (derived from latex). Do not handle the prefilled syringe if allergic to latex. Allergic reactions can cause a rash over the whole body, shortness of breath, wheezing, dizziness, swelling around your mouth or eyes, fast heart rate, and sweating. If you have any of these symptoms, stop using Fulphila and call your doctor or get emergency help right away.
• Patients with sickle cell disorder. Using Fulphila can lead to a condition called sickle cell crisis, which may be life-threatening and require discontinuation of Fulphila.
• Patients receiving radiation therapy. Fulphila may increase the risk of developing a precancerous condition called myelodysplastic syndrome (MDS) or a type of blood cancer called acute myeloid leukemia (AML).